Sunshine Biopharma (SBFM) Net Income towards Common Stockholders: 2011-2025
Historic Net Income towards Common Stockholders for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to $295,951.
- Sunshine Biopharma's Net Income towards Common Stockholders rose 124.71% to $295,951 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 8.76%. This contributed to the annual value of -$5.1 million for FY2024, which is 13.94% down from last year.
- As of Q3 2025, Sunshine Biopharma's Net Income towards Common Stockholders stood at $295,951, which was up 110.03% from -$3.0 million recorded in Q2 2025.
- Over the past 5 years, Sunshine Biopharma's Net Income towards Common Stockholders peaked at $667,116 during Q4 2021, and registered a low of -$23.5 million during Q4 2022.
- In the last 3 years, Sunshine Biopharma's Net Income towards Common Stockholders had a median value of -$1.3 million in 2023 and averaged -$1.3 million.
- The largest annual percentage gain for Sunshine Biopharma's Net Income towards Common Stockholders in the last 5 years was 161.55% (2021), contrasted with its biggest fall of 6,461.84% (2021).
- Quarterly analysis of 5 years shows Sunshine Biopharma's Net Income towards Common Stockholders stood at $667,116 in 2021, then slumped by 3,624.47% to -$23.5 million in 2022, then spiked by 94.68% to -$1.3 million in 2023, then slumped by 72.65% to -$2.2 million in 2024, then surged by 124.71% to $295,951 in 2025.
- Its last three reported values are $295,951 in Q3 2025, -$3.0 million for Q2 2025, and -$1.2 million during Q1 2025.